ArticleScientific reports2016

Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.

Wei Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.